Follow on phase III research and development sbir for project titled, broad-spectrum snakebite antidote: oral product development and IV clinical study
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH22C0030
- Awardee
-
Ophirex, Inc. UEI W452WY5E2JQ9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $23,443,944
Award facts
- Opportunity
-
- 75N91018R1PHS Solicitation number
- Contract value 100% obligated
- $23,443,943.61 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Corte Madera, CA 94925, USA
- Research
- SBIR Program Phase III Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $4,530,514 | |
| Funding Only Action | $2,217,100 | |
| Supplemental Agreement for work within scope | $2,868,831 | |
| Other Administrative Action | $0 | |
| Original award | $13,827,499 |
About this award
This is a $23,443,943.61 Firm Fixed Price definitive contract awarded by the Defense Health Agency (DHA) to Ophirex, Inc., a small business, to conduct follow-on Phase III research and development under the Small Business Innovation Research (SBIR) program. The contract is for the continued development of a broad-spectrum snakebite antidote, including an oral product and an intravenous clinical study. The contract has a total small business set-aside designation and is scheduled for completion by December 4, 2025. Ophirex has received previous SBIR Phase II and III awards from the U.S. Army Medical Command and DHA to develop treatments for snakebite envenomation and COVID-19. The company has also received a grant award from the Food and Drug Administration to support clinical trials and regulatory approval efforts for an intravenous formulation of the snakebite antidote.
Quick answers
Who was awarded contract W81XWH22C0030?
W81XWH22C0030 was awarded to Ophirex, Inc. by Defense Health Agency (Department of Defense) on April 5, 2022.
How much is contract W81XWH22C0030 worth?
The government has obligated $23,443,944 on W81XWH22C0030.
Was contract W81XWH22C0030 competed?
The extent of competition for W81XWH22C0030 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award